Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01649180
Title NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors PrECOG, LLC.
Indications

renal cell carcinoma

Therapies

Axitinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.